Shares of Ironwood (IRWD) are moving higher after its partner AbbVie (ABBV) reported Q3 Linzess sales of $315M, which beat Citizens JMP’s estimate of $241M. Analyst Jason Butler views the sales beat as a “clear positive” for Ironwood as it continues to evaluate strategic alternatives. Ironwood in late day trading is up 24%, or 36c to $1.86.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD: